Novel biomarkers for subtle myocardial involvement in type I diabetes mellitus.

Autor:	El-Saiedi SA; Division of Pediatric Cardiology, Pediatrics Unit., Hafez MH; Division of Pediatric Cardiology, Pediatrics Unit., Sedky YM; Division of Pediatric Cardiology, Pediatrics Unit., Sharaf SA; Department of Clinical Pathology., Kamel MS; Fellow of Pediatric Cardiology, Pediatrics Unit, Cairo University, Cairo, Egypt., AbdelMassih AF; Division of Pediatric Cardiology, Pediatrics Unit.
Jazyk:	angličtina
Zdroj:	Cardiovascular endocrinology & metabolism [Cardiovasc Endocrinol Metab] 2020 Nov 19; Vol. 10 (3), pp. 175-181. Date of Electronic Publication: 2020 Nov 19 (Print Publication: 2021).
DOI:	10.1097/XCE.0000000000000240
Abstrakt:	Background: Evaluation of certain biomarkers could be used to predict left ventricular (LV) and right ventricular (RV) function impairment in children with type 1 diabetes mellitus. The aim of this study was to determine the best cardiac biomarker for prediction of diabetic cardiomyopathy. Methodology: This study was designed as case-control study. A total of 55 children with type 1 diabetes mellitus (group/G1) and 55 healthy controls (G2) were subjected to echocardiography including 3D-Speckle Tracking Echocardiography and tissue Doppler imaging for assessment of RV and LV systolic and diastolic functions. As well as HbA1c, troponin I, brain natriuretic peptide (BNP), plasma cardiotrophin (CT-1), activin-A, transforming growth factor-β, and human insulin-like growth factor binding protein-7 (IGFBP-7) measurements. Results: Diabetic patients showed RV and LV systo-diastolic dysfunction compared to controls, the best predictor of LV systolic dysfunction was CT-1 (sensitivity: 69%, while IGFBP-7 was found to be the best predictor of RV systolic dysfunction (sensitivity: 63%). BNP was found to the best predictor of diastolic RV and LV dysfunction (sensitivity: 82% for both). Conclusion: CT-1 has proven to be a diagnostic superiority in LV systolic dysfunction whilst BNP continues to prove every day through our study and through many others that it is the chief marker of diastolic dysfunction and HFpEF. This potential accuracy and the increasing availability of BNP in the outpatient setting make it clear that it should be used as a screening test for diabetic patients. (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu